Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma.

ABSTRACT: We examined the meaning of metabolically active lesions on 1-month restaging nuclear imaging of patients with relapsed/refractory large B-cell lymphoma receiving axicabtagene ciloleucel (axi-cel) by assessing the relationship between total metabolic tumor volume (MTV) on positron emission tomography (PET) scans and circulating tumor DNA (ctDNA) in the plasma. In this prospective multicenter sample collection study, MTV was retrospectively calculated via commercial software at baseline, 1, and 3 months after chimeric antigen receptor (CAR) T-cell therapy; ctDNA was available before and after axi-cel administration. Spearman correlation coefficient (rs) was used to study the relationship between the variables, and a mathematical model was constructed to describe tumor dynamics 1 month after

SUBMITTER: Dean EA 

PROVIDER: S-EPMC10448428 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature